We are live on ! Find out more
SCV

Sands Capital Ventures Portfolio holdings

AUM $614M
1-Year Est. Return 19.92%
This Fund
S&P 500
This Quarter Est. Return
+15.97%
1 Year Est. Return
+19.92%
3 Year Est. Return
+166.76%
5 Year Est. Return
+157.76%
10 Year Est. Return
–
AUM
$460M
AUM Growth
+$104M
Cap. Flow
+$106M
Cap. Flow %
23.09%
Top 10 Hldgs %
88.7%
Holding
22
New
2
Increased
7
Reduced
5
Closed
1

Top Buys

Rank Stock Value
1
IKT icon
Inhibikase Therapeutics
IKT
+$27.3M
2
CPNG icon
Coupang
CPNG
+$22.4M
3
NU icon
Nu Holdings
NU
+$20.2M
4
MNDY icon
monday.com
MNDY
+$13.4M
5
DDOG icon
Datadog
DDOG
+$13.2M

Top Sells

Rank Stock Value
1
SNOW icon
Snowflake
SNOW
+$9.76M
2
BIOA
BioAge Labs
BIOA
+$5.17M
3
DASH icon
DoorDash
DASH
+$2.63M
4
KVYO icon
Klaviyo
KVYO
+$1.7M
5
SPRB
Spruce Biosciences
SPRB
+$34.8K

Sector Composition

Rank Sector Weight
1 Technology 47.33%
2 Consumer Discretionary 19.28%
3 Healthcare 17.56%
4 Financials 15.82%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KVYO icon
1
Klaviyo
KVYO
$5.26B
$143M 31.13%
3,470,694
-44,631
-1% -$1.7M
NU icon
2
Nu Holdings
NU
$73.6B
$72.7M 15.82%
7,021,159
+1,522,357
+28% +$20.2M
DASH icon
3
DoorDash
DASH
$94B
$68.3M 14.86%
407,343
-15,995
-4% -$2.63M
IKT icon
4
Inhibikase Therapeutics
IKT
$336M
$35.6M 7.74%
+10,950,000
New +$27.3M
CPNG icon
5
Coupang
CPNG
$29B
$20.3M 4.42%
924,712
+912,781
+7,650% +$22.4M
PATH icon
6
UiPath
PATH
$8.3B
$20.1M 4.38%
1,584,677
+429,431
+37% +$5.68M
DDOG icon
7
Datadog
DDOG
$91.7B
$14M 3.04%
97,788
+96,382
+6,855% +$13.2M
ACRV icon
8
Acrivon Therapeutics
ACRV
$83.6M
$12.8M 2.78%
2,122,605
– –
MNDY icon
9
monday.com
MNDY
$3.7B
$11.4M 2.47%
+48,278
New +$13.4M
TARS icon
10
Tarsus Pharmaceuticals
TARS
$3.04B
$9.41M 2.05%
170,000
– –
IOT icon
11
Samsara
IOT
$23.2B
$8.68M 1.89%
198,690
+195,518
+6,164% +$9.62M
TOST icon
12
Toast
TOST
$20.1B
$8.44M 1.84%
231,530
+227,077
+5,099% +$7.98M
TXG icon
13
10x Genomics
TXG
$7.31B
$6.92M 1.5%
481,770
– –
SNOW icon
14
Snowflake
SNOW
$114B
$6.02M 1.31%
39,007
-69,297
-64% -$9.76M
ABOS icon
15
Acumen Pharmaceuticals
ABOS
$193M
$5.88M 1.28%
3,417,075
– –
CRWD icon
16
CrowdStrike
CRWD
$221B
$5.85M 1.27%
68,400
+67,516
+7,638% +$5.61M
BIOA
17
BioAge Labs
BIOA
$487M
$4.55M 0.99%
786,353
-300,000
-28% -$5.17M
CADL icon
18
Candel Therapeutics
CADL
$897M
$3.52M 0.77%
405,837
– –
TSHA icon
19
Taysha Gene Therapies
TSHA
$1.94B
$1.25M 0.27%
724,873
– –
MASS icon
20
908 Devices
MASS
$414M
$522K 0.11%
237,258
– –
SPRB
21
Spruce Biosciences
SPRB
$151M
$301K 0.07%
9,544
-949
-9% -$34.8K
GTLB icon
22
GitLab
GTLB
$7.2B
– –
-658
Closed -$33.9K

Similar funds

T2I
Turim 21 Investimentos Rio De Janeiro, Brazil $613M AUM 14.25% 1-Year Est. Return
VAG
VisionPoint Advisory Group Dallas, Texas $613M AUM 30.37% 1-Year Est. Return
MKA
M. Kulyk & Associates Decatur, Georgia $613M AUM 22.75% 1-Year Est. Return
CSIA
Conrad Siegel Investment Advisors Harrisburg, Pennsylvania $615M AUM 21.19% 1-Year Est. Return
ATFA
All Terrain Financial Advisors Coon Rapids, Minnesota $615M AUM 30.42% 1-Year Est. Return
AA
Aire Advisors Beverly Hills, California $615M AUM 25.07% 1-Year Est. Return
FWM
Fonville Wealth Management Richmond, Virginia $612M AUM 18.82% 1-Year Est. Return
FSA
Financial Security Advisor Virginia Beach, Virginia $615M AUM 26.08% 1-Year Est. Return

Sands Capital Ventures's Q4 2024 Portfolio in Review

As of Q4 2024, Sands Capital Ventures held 22 positions worth $460M, up 29% from $356M the previous quarter. Its ten largest holdings account for 89% of the portfolio.

Sands Capital Ventures deployed $106M of net new capital in Q4 2024, opening 2 new positions and adding to 7 existing holdings. Its largest new stake was Inhibikase Therapeutics: 10,950,000 shares worth $35.6M.

By sector, the portfolio is most concentrated in Technology at 47% of assets, up from 43% a quarter earlier, followed by Consumer Discretionary and Healthcare.

On the sell side, the largest reduction was Snowflake, an estimated $9.76M trimmed.

  • Sands Capital Ventures's largest Q4 2024 buy was Inhibikase Therapeutics: 10,950,000 shares worth $35.6M.
  • Sands Capital Ventures added most to Coupang in Q4 2024, an estimated $22.4M increase.
  • Sands Capital Ventures's biggest Q4 2024 reduction was Snowflake, cutting an estimated $9.76M.
  • Sands Capital Ventures fully exited GitLab in Q4 2024, selling an estimated $33.9K.
  • Sands Capital Ventures's ten largest holdings make up 89% of its $460M portfolio in Q4 2024.
  • Sands Capital Ventures opened 2 new positions and closed 1 in Q4 2024.
  • Sands Capital Ventures's portfolio value rose 29% quarter-over-quarter to $460M.

Based on Sands Capital Ventures's 13F filing for Q4 2024, filed 13 Feb 2025.